We accelerate technology innovation in precision diagnostics to enable diseases to be detected, treated and cured earlier for better outcomes with lower costs.
Location: United States, Texas, Houston
Employees: 11-50
Total raised: $103M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.06.2022 | - | $50M | - |
| 11.01.2021 | - | $42M | - |
| 24.04.2018 | Series A | $11M | - |
Mentions in press and media 16
| Date | Title | Description |
| 03.04.2024 | Bio-Rad launches first Ultrasensitive Multiplexed Digital PCR Assay for breast cancer mutation detection in clinical research | Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System Hercules, Calif. — April 02, 2024 — Bio... |
| 03.06.2022 | NuProbe Closes $50M Funding | NuProbe Global, a Houston, TX- and Shanghai, China-based genomics and molecular diagnostics company, raised $50M in funding. The round was co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing investors Sequ... |
| 26.07.2021 | NuProbe : Announces New Research and New Product on DNA Microsatellite Instability | HOUSTON, July 26, 2021 /PRNewswire/ -- NuProbe Global, a genomics and molecular diagnostics company specialized in ultrasensitive oncology assays, announced research on DNA microsatellites published today in Nucleic Acids Research. Simultan... |
| 26.07.2021 | NuProbe Announces New Research and New Product on DNA Microsatellite Instability | |
| 07.07.2021 | China Launches the World's Largest Real-World Study on Screening and Diagnosis of Male Reproduction-Related Genes | |
| 22.02.2021 | NuProbe Launches Liquid Biopsy Pan-Cancer NGS Panel | |
| 11.01.2021 | NuProbe Raises $42M in Funding | NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round. The round was led by BioTrack Capital and Yonghua Capi... |
| 11.01.2021 | NuProbe Raises $42M in Funding | NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round. The round was led by BioTrack Capital and Yonghua Capi... |
| 11.01.2021 | NuProbe Closes $42M Fundraising | |
| 11.01.2021 | NuProbe Raises $42M in Funding | NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round. The round was led by BioTrack Capital and Yonghua Capi... |
Show more